M. A. Sigov

M. A. Sigov

Auto-generated profile, based on publicly available information

M. A. Sigov

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in Diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
VKV. V. Krylov
V. V. Krylov
NLN. S. Legkodimova
N. S. Legkodimova
TKT. Yu. Kochetova
T. Yu. Kochetova
VPV. M. Petriev
V. M. Petriev
MSM. A. Sigov
M. A. Sigov
AKAndrei Kaprin
Andrei Kaprin
INTRODUCTION: The results of studies of clinical potential of a new domestic radiopharmaceutical 177Lu-DOTA-PSMA in patients with metastatic castration-resistant prostate cancer are presented in this article.OBJECTIVE: The pharmacokinetics, safety and tolerability of radiopharmaceutical were studied. Tolerability of increasing activities — 5.0, 7.5 and 10.0 GBq was investigated.MATERIALS AND METHODS: The study included 12 patients with metastatic castration-resistant prostate cancer, who progressed after previous treatment. The first 4 patients was treated by 5 GBq of 177Lu DOTA-PSMA, the next 4 patients of the second group was treated by 7.5 GBq, and the 4 patients of the third group was treated by 10 GBq. Radiopharmacokinetics was studied by whole-body scintigraphy, SPECT/CT, blood and urine radiometry. The radiation-absorbed dose (RAD) of metastases and organs at risk was studied by clinical dosimetry. Safety assessment also was studied by hematological status. All patients was taken a complete blood count, a biochemical blood test before course of therapy treatable and during the case study.RESULTS: Study data showed high accumulation of 177Lu-DOTA-PSMA the in pathological focus, the distribution in the body conformed to the previous data of PET/CT study. Blood radiometry showed that 177Lu-DOTA-PSMA rapidly excreted from the bloodstream (during the first hours after injection). Urine radiometry showed that, more than half of the injected dose was excreted during 2 days (from 34.4% to 88.8%).DISCUSSION: During the study was solicited increasing of pain syndrome, dry mouth. Most patients had moderate myelosuppression. Changes in hematological parameters had a transistor character, the adverse event resolved without consequences in 5 week. 4th grade of NCI CTCAE hematological toxicity criteria wasn’t identified. Serious adverse events weren’t identified too.CONCLUSIONS: Radiopharmaceutical demonstrated high affinity for tumor tissue and safety in the clinical use. Data, which demonstrating a high potential anti-tumor efficacy of radiopharmaceutical, were obtained. Dosimetric studies showed radiation safety of work with radiopharmaceutical for the personnel.

29 March 2024 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
TKT. Yu. Kochetova
T. Yu. Kochetova
VKV. V. Krylov
V. V. Krylov
MSM. A. Sigov
M. A. Sigov
VRV. O. Ripp
V. O. Ripp
ASA. Yu. Shurinov
A. Yu. Shurinov
AKAndrei Kaprin
Andrei Kaprin
Introduction: 225Ac-PSMA is a promising drug for radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). Despite the large number of studies in this area, the optimal therapeutic activity of the drug is a debatable issue. The purpose of this study is to evaluate the safety of a single dose of 225Ac-PSMA at a fixed dosage (regardless of patient weight) of 6, 9 and 12 MBq.Material and methods: The study included 9 patients, 3 in each group, with mCRPC progressing against the background of standard treatment (from 1 to 6 lines of mCRPC therapy in history). The observation period was 5 weeks, instrumental, laboratory and clinical indicators were used to assess safety. 225As-PSMA was manufactured directly in the clinic in accordance with the order of the Ministry of Health of Russia 1218n dated 11/12/2020.Results: During the observation period, one patient from the group with the lowest administered activity had a serious adverse event (hospitalization due to pneumonia). When discussing this case, it was concluded that there was no connection with the drug, since pneumonia in this patient was not accompanied by leukopenia or neutropenia. All patients experienced dry mouth. In patients who received 9 and 12 MBq a decrease in the salivary gland function was recorded by scintigraphy. In two patients, severe weakness was revealed, in one of them the weakness could be associated with pneumonia, in the other patient, the weakness was most likely caused by the therapy. No cases of nephrotoxicity were recorded. Hematological toxicity was temporary reversible; no additional treatment was required in any of the cases. The most common adverse event: leukopenia, neutropenia (78 % of patients), grade III leukopenia was observed in two (22 %) patients, grade III neutropenia in one (11 %) patient.Conclusions: A single administration of 225Ac-PSMA in the studied range of activities was safe, dose-limiting toxicity was not achieved.

28 June 2024 in Head and Neck Tumors (HNT)
Verified
Journal Article
Open access
PDF file
ASA. Yu. Shurinov
A. Yu. Shurinov
EBE. V. Borodavina
E. V. Borodavina
VKV. V. Krylov
V. V. Krylov
MSM. A. Sigov
M. A. Sigov
АRАндрей Алексеевич Andrei Rodichev
Андрей Алексеевич Andrei Rodichev
AKAndrei Kaprin
Andrei Kaprin
The radioiodine therapy is a one of the basic elements at combined treatment of differentiated thyroid cancer and is an alternative method for patients with distant metastases and a potentially high risk of tumor recurrence. It has been used in clinical practice for more than 80 years. The first report on the phenomenon of accumulation of 130I/131I in a metastatic focus of differentiated thyroid cancer was published by A. Keston et al. in 1942, and in 1946, the production of 131I was established, and the drug became available. In our country, radioiodine therapy has been widely used for the treatment of differentiated thyroid cancer since 1982.This article presents methodological recommendations for radioiodine therapy of patients with differentiated thyroid cancer, provides a modern examination algorithm, discusses the basic principles of laboratory, instrumental diagnostics and treatment approaches treatment of this disease.

30 December 2023 in Head and Neck Tumors (HNT)
Verified
Journal Article
Open access
PDF file
FSF. E. Sevryukov
F. E. Sevryukov
ВПВ. В. Полькин
В. В. Полькин
YPYu. A. Panaseikin
Yu. A. Panaseikin
MSM. A. Sigov
M. A. Sigov
RZR. F. Zibirov
R. F. Zibirov
ЮПЮ. А. Панасейкин
Ю. А. Панасейкин
Introduction. Head and neck cancer is the 7th most common malignancy worldwide; squamous cell carcinoma of the oral mucosa are almost a third of tumors of that localization. Metastatic lesions of the neck lymph nodes are an unfavorable prognostic factor for malignant tumors of that location since it is associated with a 50 % decrease in overall survival. In this regard, the detection of metastases to the neck lymph nodes is an important component of high-quality oncological care for patients with that pathology.Aim. To evaluate the efficiency of sentinel lymph node biopsy in squamous cell carcinoma of cavity of mouth mucosa cT1–2N0М0.Materials and methods. 72 patients were included in trial at the age from 21 to 74 (mean 57.3) with confirmed squamous cell carcinoma of cavity of mouth mucosa cT1–2N0М0. No evidence of regional metastasis, by preoperative examination, including ultrasound, computed tomography with intravenous contrast was observed. All patients received radioisotope research to determine localization of sentinel lymph nodes, and then biopsy of that nodes was performed. Before obtaining information about the status of the sentinel lymph node, radical neck dissection was not performed. Pathology report with immunohistochemical investigation was performed by pathologist of A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia.Results. When assessing efficiency of sentinel lymph node method, true positives results (detection of metastasis in sentinel lymph node) were achieved in 3 (4.17 %) out of 72 cases. Follow up time was from 1 to 69 months. Among those cases, where metastasis in sentinel lymph nodes were not detected, relapse in regional lymph nodes was developed in 3 (4.35 %) out of 69 cases. Radical neck dissection was performed in cases with metastasis in sentinel lymph nodes. The specificity of method was 95 %, the predictive value of a negative result was 0.04.Conclusion. Sentinel lymph neck node biopsy is an effective method of subclinical locoregional metastases detection in cancer of oral mucosa cT1–2N0M0. In our study of sentinel lymph neck node biopsy, oncological outcomes were comparable to radical neck dissection, with fewer postoperative complications.

29 October 2025 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
VTV.K. Tishchenko
V.K. Tishchenko
OVO.P. Vlasova
O.P. Vlasova
TRT.P. Ryzhikova
T.P. Ryzhikova
VSValeriy Stepanenko
Valeriy Stepanenko
MSM.A. Sigov
M.A. Sigov
AKAndrei Kaprin
Andrei Kaprin
Intra-arterial radioembolization (RE) with radiopharmaceuticals based on microspheres labeled with beta-emitting radionuclides is one of the most promising methods of inoperable liver cancer treatment. Phase 1 and 2 of clinical trials of a domestic radiopharmaceutical based on albumin microspheres with a diameter of 20—40 μm, labeled with rhenium-188 («MSA 20—40 μm, 188Re») has already been completed. Objective. To study the distribution of radiopharmaceutical «MSA 20—40 μm, 188Re» in the body of patients after radioembolization, to determine the individual absorbed doses of tumor lesions and risk organs of patients, and the local radiation doses of personnel. Material and methods. Radiopharmaceutical «MSA 20—40 μm, 188Re» with activities ranged from 3.1 MBq to 6.5 MBq was used for intra-arterial RE in 50 patients (18 females and 32 males) with primary liver cancer (C22.0, C22.1, C22.2, C22.9) and metastatic liver cancer (C18.0, C18.6, C18.7, C19.0, C20.0, C97). Scintigraphy and SPECT/CT of the whole body were performed at 1, 24, 48, and 72 h after RE. Radiometry of urine samples, which was taken for 48 h after RE, was carried out. The calculation of absorbed doses was performed according to recommendations of Medical Internal Radiation Dose (MIRD). To measure local radiation doses of medical personnel luminescent microdosimeters were used. Results. The urinary excretion of 188Re in patients of Phase I of clinical trials was on averaged 22.8%, decreasing to 13.6% after updating of radiopharmaceutical synthesis technology. A small (3.4%-13.4%) pulmonary shunt was observed in all patients. Absorbed doses in tumor lesions ranged from 4.6 Gy to 68.5 Gy, depending on administered activities and lesions volume. The values of individual radiation doses in critical organs of patients were significantly lower than the commonly applied dose constraints in radiotherapy. No personnel dose limits were exceeded in accordance with Radiation safety standards-99/2009. Conclusion. High stability of «MSA 20—40 μm, 188Re» during radioembolization procedure ensures the delivery of significantly higher absorbed doses in tumor foci as compared with risk organs of patients with inoperable liver cancer.

12 August 2026 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
EBE. V. Borodavina
E. V. Borodavina
ABA. S. Bakhmat
A. S. Bakhmat
MSM. A. Sigov
M. A. Sigov
VKV. V. Krylov
V. V. Krylov
EKE. I. Kupriyanova
E. I. Kupriyanova
This article presents a rare clinical observation of an aggressive course of papillary thyroid carcinoma in a 15-year-old female patient, featuring distant liver metastasis, which is unique for the pediatric age group. All stages of diagnosis are described. Data on the comprehensive treatment provided are presented: surgical (radical thyroidectomy with bilateral selective neck lymph node dissection) and radioiodine therapy (RAIT) (4 courses with a total activity of 15 GBq). Following RAIT, complete regression of metastases in the lungs and cervical lymph nodes was achieved, and stabilization of the liver lesions was noted, with a decrease in radiopharmaceutical uptake according to scintigraphic studies and a reduction in thyroglobulin levels by more than 3.5 times. The conclusion is made about the possibility of achieving high efficacy of RAIT in the presence of metastases not only to the lungs but also to the liver. The importance of a multidisciplinary approach and oncological vigilance in patients with high-risk factors for disease recurrence and progression is emphasized.